Moderna Stock Climbs 330% Over Six Months, BFM Business Reports
Moderna stock climbed roughly 330% over six months, marking a striking turnaround for a pharmaceutical laboratory whose revenue tumbled after the peak of the global health crisis, BFM Business reported.
- Moderna’s annual revenue plunged from $19.3 billion in 2022 down to $1.9 billion in 2025 as demand for its coronavirus vaccine receded.
- The company is seeking regulatory approval for intismeran autogence, a customized therapeutic cancer vaccine developed alongside Merck.
- Clinical trial results for the melanoma treatment showed a 42% reduction in the risk of recurrence or death compared to the standard reference treatment alone.
Revenue at the Cambridge, Massachusetts-headquartered biotechnology firm reached just 800 million dollars in 2020 before surging to 19.3 billion dollars in 2022, according to company figures reported by BFM Business. By 2025, those sales dropped back down to approximately 1.9 billion dollars.
“Nous sommes passés de zéro vente à 18 milliards de dollars en une année […] Puis nous sommes passés de 18 à 2 milliards de dollars,” Stéphane Bancel, the French chief executive officer of Moderna, told BFM Business in June, according to BFM BUSINESS.
Moderna is returning to its founding strategy of applying messenger RNA technology to conditions beyond viral infections. The company and its partner Merck are testing a personalized cancer vaccine tailored to individual patient tumors.
The advanced trial in melanoma demonstrated that the customized vaccine lowered the risk of disease recurrence or death by 42% against the standard single-agent treatment. Beyond skin cancer, both partners are evaluating the vaccine candidate against lung, kidney, and bladder tumors.
Moderna announced during its investor day on November 12, 2026, that it aims to file a marketing application with the Food and Drug Administration before the end of the year. Subject to regulatory clearance by the U.S. agency, commercial launch could occur in 2027.
Market analysts project the global market for personalized cancer vaccines to climb from approximately 208 million dollars in 2024 to 1.45 billion dollars by 2030, according to data from Grand View Research. In France, the market is estimated to expand from 7 million dollars to 52 million dollars over the same period.
| Financial Metric | 2020 | 2022 | 2025 |
|---|---|---|---|
| Annual Revenue | ~$800 Million | $19.3 Billion | ~$1.9 Billion |
The enthusiasm among investors has faced sharp corrections alongside clinical updates. Following an increase of nearly 180% during a single trading session in August, Moderna shares fell by more than 25% on October 22 after detailed cancer vaccine data failed to match higher expectations on Wall Street.
Barron’s reported that Moderna anticipates cash disbursements of roughly 4 billion dollars in 2027, followed by annual expenditures between 4 billion and 4.5 billion dollars through 2030. International vaccine sales recently contributed to a 29% quarterly revenue increase, but the company has not posted an annual profit since the pandemic era.
Whether the upcoming regulatory filings and manufacturing scaling for personalized vaccines will establish a sustainable revenue stream remains to be determined.
Stéphane Bancel, born in Marseille in 1972, studied engineering at CentraleSupélec and the University of Minnesota before earning an MBA from Harvard Business School. He served as CEO of French diagnostics firm BioMérieux from 2007, where he was credited with improving margins, before joining Moderna as chief executive in 2011.
As of May 2023, his net worth was estimated at US$4.1 billion, with an ownership stake of about 8% in Moderna. He is also a partner at Flagship Pioneering and has sat on the boards of Indigo Agriculture, Boston’s Museum of Science, and Qiagen.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.